COVID-19 in patients with end stage kidney disease at a large community hospital in Eastern Saudi Arabia. A prospective study

Article Figures & Data

Table 1

- Patients’ characteristics: upper panel; symptoms and laboratory findings: lower panel.

Characteristics	n (%)
Total number of patients (episodes)	30 (31)
Age, year, median (IQR)	63 (55-75)
Female	17 (56 %)
BMI (kg/m²), median (IQR)	28 (23-31)
Comorbidities
Diabetes mellitus	22 (73)
Hypertension	29 (97)
Coronary artery disease	14 (47)
Congestive heart failure	11 (37)
Smoking	1 (3)
Sickle cell disease	2 (6)
History of malignancy	6 (20)
COPD	3 (10)
Symptoms and laboratory findings
Admission symptoms
Fever	15 (48)
Cough	16 (52)
Shortness of breath	19 (61)
Loss of smell	17 (55)
Admission hematologic markers median (IQR)
Hemoglobin g/dL	10.5 (8.5-11.5)
Neutrophil count 10³ µl	5 (3.3-5.2)
% Neutrophil	69 (59-80)
Lymphocyte count 10³ µl	1.1 (0.8-1.4)
% lymphocyte	18 (12-31)
Admission maximum inflammatory markers, median (IQR)
CRP mg/L	3.1 (1.4-7.4)
Ferritin ng/ml	834 (594-1964)
BNP	973 (117-1386)
D-Dimer	2.0 (1.08-6.4)

IQR: interquartile range, BMI: body mass index, COPD: chronic obstructive pulmonary disease, CRP: C reactive protein, BNP: B-type natriuretic peptide, %: percentage

Table 3

- Clinical outcome of patients with end stage kidney disease and COVID-19.

Clinical outcome	n (%)
Pneumonia	16 (52)
ICU admission	5 (17)
Mechanical ventilation	5 (17)
Pulmonary embolism	1 (3)
Vasopressors	5 (17)
Length of stay, days (mean±SD)	13 ± 2.4
Mortality	5 (17)
SD: standard deviation, ICU: intensive care unit